Fore Biotherapeutics

Fore Biotherapeutics

  • Founded: 2011
  • Location: Philadelphia, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2a
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: FORE8394
  • Product link:
  • Funding: $75M D Aug 2023; $57M C Sep 2020
  • Investors: SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management, Samsung Securities

job board

Short description:

BRAF-Inhibitors, In-licensing others

Drug notes:

Contact us to add description:

Long description:

Fore Biotherapeutics is using precision oncology to develop innovative treatments for cancer patients. Current existing cancer drugs target the most common cancer-triggering mutations, however, most mutations in cancer are infrequent, understudied and unaddressed. Fore is using their high-throughout, high-precision functional genomics approach to find therapeutic options for patients whose cancers are driven by a multitude of rarer cancer-triggering mutations. This involves identifying targets and matching them to candidate compounds that can reduce oncogenic signaling pathways. Fore’s lead program, FORE8394, is a small molecule inhibitor of mutated BRAF that is being investigated for CNS and solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy